Wellington Management Group LLP Sells 431,778 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Wellington Management Group LLP trimmed its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 6.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,617,055 shares of the company's stock after selling 431,778 shares during the period. Wellington Management Group LLP owned about 13.23% of Immunocore worth $195,203,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. FMR LLC lifted its holdings in Immunocore by 0.5% during the 3rd quarter. FMR LLC now owns 4,836,040 shares of the company's stock valued at $150,546,000 after purchasing an additional 23,436 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Immunocore by 8.0% during the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after buying an additional 196,530 shares in the last quarter. Two Sigma Advisers LP raised its stake in shares of Immunocore by 65.6% in the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company's stock valued at $23,587,000 after acquiring an additional 300,200 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after acquiring an additional 109,206 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Immunocore by 7,437.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company's stock worth $2,872,000 after acquiring an additional 91,033 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.10% of the company's stock.

Immunocore Trading Down 3.6 %

Shares of IMCR stock traded down $0.98 on Monday, reaching $26.28. The company had a trading volume of 766,874 shares, compared to its average volume of 445,406. The company has a 50-day moving average of $29.68 and a 200-day moving average of $30.72. Immunocore Holdings plc has a 12 month low of $24.84 and a 12 month high of $63.94. The stock has a market cap of $1.31 billion, a PE ratio of -27.66 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IMCR shares. Mizuho decreased their target price on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday. HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $71.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $65.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.